Breaking Finance News

Zacks Investment Research downgraded Proteostasis Therapeutics Inc (NASDAQ:PTI) to Sell in a report released today.

Showing a price of $12.52, Proteostasis Therapeutics Inc (NASDAQ:PTI) traded 2.32% higher on the day. With the last stock price close up 4.06% from the 200-day average, compared with the Standard & Poor’s 500 Index which has decreased -0.01% over the date range. PTI has recorded a 50-day average of $13.86 and 200-day moving average of $12.31. 136,721 shares of Proteostasis Therapeutics Inc traded hands, down from ann average volume of 168,134

Zacks Investment Research has downgraded Proteostasis Therapeutics Inc(NASDAQ:PTI) to Sell in a report released Thursday September 15 2016.

See Graphic Below:

Proteostasis Therapeutics Inc (NASDAQ:PTI)

With a market capitalization of $0.0, Proteostasis Therapeutics Inc has a one-year low of $5.27 and a 52 week high of $20.63 with a P/E ratio of 0.

Brief Synopsis On Proteostasis Therapeutics Inc (NASDAQ:PTI)

Proteostasis Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in discovery and development of therapeutics that treat diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. It has developed the Disease Relevant Translation (DRT) technology platform, a drug screening approach for identifying highly translatable therapeutics based on predictive and functionally pertinent phenotypic assays and disease relevant models. Using this platform, it has identified a new class of small molecules, amplifiers that modulate proteins in the proteostasis network. It is developing and intend to commercialize its lead amplifier of CFTR protein, PTI-428, to improve CFTR protein function. It also focuses on developing PTI-NC-733, PTI-130, and Usp14 program and unfolded protein response (UPR) program. PTI-130 is a small molecule amplifier.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *